A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam
Authors:
- Kazuyo TamuraKTKazuyo Tamura
- Reiko SatoRSReiko Sato
- Hazuki SamejimaHSHazuki Samejima
- Yusuke TanigawaraYTYusuke Tanigawara
- Takao TakahashiTTTakao Takahashi
- 1 December 2004
- journal article
- Published by Elsevier in Brain and Development
- Vol. 26 (8) , 530-534
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19Brain and Development, 2004
- Evidence of Polymorphic CYP2C19 Involvement in the Human Metabolism of N-DesmethylclobazamTherapeutic Drug Monitoring, 2002
- Polymorphism of cytochrome P450 and xenobiotic toxicityToxicology, 2002
- Clinical relevance of genetic polymorphisms in the human CYP2C subfamilyBritish Journal of Clinical Pharmacology, 2001
- Effect of Felbamate on Clobazam and Its Metabolite Kinetics in Patients With EpilepsyTherapeutic Drug Monitoring, 1999
- Pharmacokinetic Interactions Between Antiepileptic DrugsClinical Pharmacokinetics, 1996
- Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in HumansBiochemistry, 1994
- Interactions Between Clobazam and Standard Antiepileptic Drugs in Patients with EpilepsyTherapeutic Drug Monitoring, 1992
- Effects of Age and Antiepileptic Drugs on Plasma Levels and Kinetics of Clobazam and N‐DesmethylclobazamBasic & Clinical Pharmacology & Toxicology, 1990
- Slow Omeprazole Metabolizers Are Also Poor S-Mephenytoin HydroxylatorsTherapeutic Drug Monitoring, 1990